← All companies

COAG

Hemab Therapeutics Holdings, Inc.

COAG Nasdaq Biological Products, (No Diagnostic Substances) EDGAR ↗

$45.00

-2.55 -5.36%

Key statistics

from XBRL data in SEC filings

Market cap

$2.10B

Revenue (TTM)

—

Net income (TTM)

—

EPS (TTM)

—

P/E ratio

—

Dividend yield

—

Free cash flow

—

Cash

$49.9M

Total assets

$175M

Gross margin

—

52-week range

$23.00 – $52.15

Recent SEC filings

39 most recent

Annual, quarterly & current reports

10-Q Quarter ended 2026-03-31 May 21, 2026 8-K Results of operations (earnings release) May 21, 2026 8-K Director or officer change May 11, 2026 8-K Amended charter or bylaws; Other events May 4, 2026

Other filings

4 Jun 17, 2026 4 May 21, 2026 4 May 14, 2026 3 May 14, 2026 SCHEDULE 13G May 11, 2026 4 May 11, 2026 SCHEDULE 13D May 11, 2026 SCHEDULE 13G May 8, 2026 4 May 6, 2026 4 May 6, 2026 4 May 4, 2026 4 May 4, 2026 4 May 4, 2026 S-8 May 4, 2026 424B4 May 1, 2026 EFFECT Apr 30, 2026 3 Apr 30, 2026 3 Apr 30, 2026 3 Apr 30, 2026 3 Apr 30, 2026 3 Apr 30, 2026 3 Apr 30, 2026 3 Apr 30, 2026 3 Apr 30, 2026 3 Apr 30, 2026 3 Apr 30, 2026 S-1MEF Apr 30, 2026 CERT Apr 30, 2026 S-1/A Apr 30, 2026 S-1/A Apr 28, 2026 8-A12B Apr 27, 2026 S-1/A Apr 27, 2026 S-1 Apr 10, 2026 DRS/A Apr 2, 2026 DRS Feb 27, 2026